Clinical Trial Update: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update announcing the evaluation of FORE8394 in participants with cancers harboring BRAF alterations, including high-grade glioma, low-gr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma
• Low-grade Glioma
• Solid Tumors

Drugs mentioned

• FORE8394

Snippet

Sponsor: Fore Biotherapeutics | Conditions: Cancer Harboring BRAF Alterations, HGG | Phase 2 | Status: RECRUITING